Cargando…
Interchangeability, immunogenicity and safety of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (Synflorix) and 13-valent-PCV (Prevenar13) schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial
BACKGROUND: Aboriginal children living in remote communities are at high risk of early and persistent otitis media. Streptococcus pneumoniae and non-typeable Haemophilus influenzae (NTHi) are primary pathogens. Vaccines with potential to prevent early OM have not been evaluated in this population. W...
Autores principales: | Leach, Amanda Jane, Mulholland, Edward Kim, Santosham, Mathuram, Torzillo, Paul John, McIntyre, Peter, Smith-Vaughan, Heidi, Wilson, Nicole, Arrowsmith, Beth, Beissbarth, Jemima, Chatfield, Mark D., Oguoma, Victor M., Licciardi, Paul, Skull, Sue, Andrews, Ross, Carapetis, Jonathan, McDonnell, Joseph, Krause, Vicki, Morris, Peter Stanley |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930582/ https://www.ncbi.nlm.nih.gov/pubmed/33681756 http://dx.doi.org/10.1016/j.jvacx.2021.100086 |
Ejemplares similares
-
Otitis media outcomes of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine and 13-valent pneumococcal conjugate vaccine schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial
por: Leach, Amanda Jane, et al.
Publicado: (2021) -
Pneumococcal conjugate vaccines PREVenar13 and SynflorIX in sequence or alone in high-risk Indigenous infants (PREV-IX_COMBO): protocol of a randomised controlled trial
por: Leach, Amanda Jane, et al.
Publicado: (2015) -
10-Valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine (PHiD-CV10) versus 13-valent pneumococcal conjugate vaccine (PCV13) as a booster dose to broaden and strengthen protection from otitis media (PREVIX_BOOST) in Australian Aboriginal children: study protocol for a randomised controlled trial
por: Oguoma, Victor M, et al.
Publicado: (2020) -
Comparative Immunogenicity of 7 and 13-Valent Pneumococcal Conjugate Vaccines and the Development of Functional Antibodies to Cross-Reactive Serotypes
por: Grant, Lindsay R., et al.
Publicado: (2013) -
Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
por: Perdrizet, Johnna, et al.
Publicado: (2021)